Market Overview:

The insomnia market is experiencing rapid growth, driven by rising prevalence of sleep disorders, advancements in diagnostic technologies and growing geriatric population. According to IMARC Group's latest research publication, "Insect Feed Market Report by Product Type (Meal Worms, Fly Larvae, Silkworms, Cicadas, and Others), Application (Aquaculture, Pig Nutrition, Poultry Nutrition, Dairy Nutrition, and Others), and Region 2025-2033", The global insomnia market size was valued at USD 5.34 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 6.78 Billionby 2033, exhibiting a CAGR of 2.55%during 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/insomnia-market/requestsample

Our report includes:

• Market Dynamics
• Market Trends and Market Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Insomnia Market

• Rising Prevalence of Sleep Disorders:

  Sleep disorders, as a result of modern lifestyles as well as the increasing prevalence of sleep-related behavioural issues, constitute a significant contributor to the insomnia markets growth. Stressful modern jobs, shifts in, sleep and wake patterns, excessive screen time and associated factors all contribute to sleep problems, for example according to the American Sleep Association, roughly 70 million Americans suffer from sleep disorders where insomnia is the most prevalent. The increase in insomnia as an issue globally, has resulted in subsequent increases in mental health-related issues such as anxiety and depression each of which can express as a sleep issue/anxiety often. As knowledge and importance of sleep's overall health benefits in sleep improves, more individuals are seeking medical intervention which again drives both an intention to consume pharmacological products as well as non-pharmacological services.

• Advancements in Diagnostic Technologies:

  New tools for diagnosis are revolutionizing the insomnia marketplace by improving the ability to accurately identify sleep disturbances. New tools are equipped with technologies such as wearable sleep trackers, polysomnography devices, and monitoring devices that accurately capture and record sleep patterns to allow for improved treatment for insomnia and other sleep disorders. Take for example, in October of 2024, SleepScore Labs introduced an AI-based platform, Sleep.AI, which was built off of 500 million hours of sleep data, to provide more accurate diagnostics. The use of these new tools can help clinicians find the treatment that is most appropriate for the patient and improve outcomes. It also helps to ensure that patients are being seen and if a sleep disturbance is identified helps to further engage the patient in obtaining treatment. By improving accuracy to find more treated patients, there is more market growth because there is an increase in demand to be treated with specialized treatments and devices.

• Growing Geriatric Population:

  The global population that is aging is a key factor for the insomnia market, since older adults are more at risk of sleep issues. Often, older adults face changes in their biological rhythms due to age which can disturb sleep thanks to multiple chronic diseases and medication side effects. Research has shown that greater than 50% of adults aged 60 and older have sleep issues, which represents a significant market opportunity. Eisai has recognized this opportunity and developed lemborexant (a drug for the treatment of insomnia in older adults). Overall, the aging population is a consideration in the growing demand for sleep treatment options unique to the age group of older adults, many of which may be non-pharmacological in nature.

Key Trends in the Insomnia Market

• Shift Toward Non-Pharmacological Therapies:

  A prominent trend in the insomnia market is the growing preference for non-pharmacological treatments, such as cognitive behavioral therapy for insomnia (CBT-I). Patients and providers are increasingly wary of the side effects of sleep medications, like dependency and cognitive impairment. In August 2024, Big Health received FDA clearance for SleepioRx, a digital CBT-I platform, demonstrating the rising acceptance of tech-driven solutions. This trend reflects a broader movement toward holistic, patient-centered care, with therapies like yoga and mindfulness gaining traction. These approaches improve adherence and long-term outcomes, reshaping the market landscape.

• Integration of Digital Health Solutions:

  Digital health technologies, including sleep apps and wearable devices, are revolutionizing insomnia management. These tools offer real-time sleep monitoring and personalized interventions, enhancing patient engagement. For example, HoneyNaps’ SOMNUM platform, launched in 2021, uses AI to diagnose and treat insomnia through non-contact sleep analysis. The rise of telemedicine further supports this trend by enabling remote consultations and therapy delivery, particularly in underserved regions. As consumers embrace tech-driven solutions for convenience and accessibility, the market sees increased adoption of digital therapeutics, driving innovation and expanding treatment options.

• Focus on Personalized Medicine:

  Personalized medicine is gaining momentum in the insomnia market, with treatments tailored to individual patient profiles. Advances in genomics and neurobiology allow providers to address specific causes of insomnia, such as genetic predispositions or unique sleep patterns. For instance, research into biomarkers is enabling the development of targeted therapies that minimize side effects. This trend is evident in the growing use of combination therapies, where pharmacological and non-pharmacological approaches are customized. By prioritizing efficacy and safety, personalized medicine enhances patient outcomes, fostering market growth through innovative and precise treatment strategies.

We explore the factors propelling the insomnia market growth, including technological advancements, consumer behaviors, and regulatory changes.

Leading Companies Operating in the Insomnia Industry:

• Astellas Pharma Inc.
• Aurobindo Pharma Limited
• Biocodex
• Eisai Co. Ltd.
• Mallinckrodt Pharmaceuticals
• Merck & Co. Inc.
• Neurim Pharmaceuticals Inc.
• Pfizer Inc.
• Sanofi S.A.
• Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)
• Takeda Pharmaceutical Company Limited
• Vanda Pharmaceuticals Inc.

Insomnia Market Report Segmentation:

By Therapy Type:

• Non-Pharmacological Therapy

• Hypnotherapy
• Cognitive Behavioral Therapy
• Medical Devices
• Others
  • Pharmacological Therapy
• Prescription Sleep Aids
• Over-The-Counter Sleep Aids

The pharmacological therapy segment is driven by rising demand for effective insomnia treatments, pharmaceutical innovations, and the global prevalence of insomnia, with strategic collaborations and regulatory approvals enhancing market growth.

By Drug Class:

• Antidepressants
• Melatonin Antagonist
• Benzodiazepines
• Nonbenzodiazepines
• Orexin Antagonist
• Others

Benzodiazepines lead with 28.9% market share in 2024, driven by demand for effective anxiolytics and sedatives, ongoing research to improve formulations, and the aging population seeking treatments for anxiety and sleep disturbances.

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Hospital pharmacies thrive on the need for specialized services in healthcare facilities, while retail pharmacies benefit from accessibility and convenience; drug stores cater to consumer preferences for one-stop shopping, and online pharmacies gain from the adoption of digital health solutions and e-commerce.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the largest market share at over 36.4% in 2024, driven by increased awareness and diagnosis of insomnia, a high prevalence of lifestyle factors contributing to sleep disorders, and advances in medical research and technology enhancing treatment efficacy.

Research Methodology:

The report employs a comprehensive research methodology, combining primary and secondary data sources to validate findings. It includes market assessments, surveys, expert opinions, and data triangulation techniques to ensure accuracy and reliability.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145